Literature DB >> 10841508

Proteinases in cardiovascular aneurysms and rupture: targets for therapy?

P Carmeliet1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10841508      PMCID： PMC300866          DOI： 10.1172/JCI10242

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  15 in total

1.  Cell and extracellular matrix rejection in arterial concordant and discordant xenografts in the rat.

Authors:  E Allaire; C Mandet; P Bruneval; S Bensenane; J P Becquemin; J B Michel
Journal:  Transplantation       Date:  1996-09-27       Impact factor: 4.939

2.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.

Authors:  S Heymans; A Luttun; D Nuyens; G Theilmeier; E Creemers; L Moons; G D Dyspersin; J P Cleutjens; M Shipley; A Angellilo; M Levi; O Nübe; A Baker; E Keshet; F Lupu; J M Herbert; J F Smits; S D Shapiro; M Baes; M Borgers; D Collen; M J Daemen; P Carmeliet
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

Review 3.  Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem.

Authors:  R W Thompson
Journal:  Curr Opin Cardiol       Date:  1996-09       Impact factor: 2.161

4.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms.

Authors:  R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

5.  MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial.

Authors:  R W Thompson; B T Baxter
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

6.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.

Authors:  P Carmeliet; L Moons; R Lijnen; M Baes; V Lemaître; P Tipping; A Drew; Y Eeckhout; S Shapiro; F Lupu; D Collen
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

7.  Postinfarction ventricular septal rupture: the Wessex experience.

Authors:  M J Dalrymple-Hay; J L Monro; S A Livesey; R K Lamb
Journal:  Semin Thorac Cardiovasc Surg       Date:  1998-04

8.  Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.

Authors:  E Allaire; D Hasenstab; R D Kenagy; B Starcher; M M Clowes; A W Clowes
Journal:  Circulation       Date:  1998-07-21       Impact factor: 29.690

9.  Demonstration of interstitial collagenase in abdominal aortic aneurysm disease.

Authors:  E Irizarry; K M Newman; R H Gandhi; G B Nackman; V Halpern; S Wishner; J V Scholes; M D Tilson
Journal:  J Surg Res       Date:  1993-06       Impact factor: 2.192

10.  Plasminogen activator expression in human atherosclerotic lesions.

Authors:  F Lupu; D A Heim; F Bachmann; M Hurni; V V Kakkar; E K Kruithof
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-09       Impact factor: 8.311
View more
  10 in total

Review 1.  The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.

Authors:  A Luttun; M Dewerchin; D Collen; P Carmeliet
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

2.  When it is inflamed, it hurts.

Authors:  R Baliga; J Narula
Journal:  J Nucl Cardiol       Date:  2001 Mar-Apr       Impact factor: 5.952

3.  Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy.

Authors:  Essa M Essa; Michael R Zile; Robert E Stroud; Allison Rice; Richard J Gumina; Carl V Leier; Francis G Spinale
Journal:  J Card Fail       Date:  2012-06       Impact factor: 5.712

4.  Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases.

Authors:  Hazem Abdul-Hussien; Ratna G V Soekhoe; Ekkehard Weber; Jan H von der Thüsen; Robert Kleemann; Adri Mulder; J Hajo van Bockel; Roeland Hanemaaijer; Jan H N Lindeman
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

5.  Deficiency of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 accelerates atherogenesis in apolipoprotein E-deficient mice.

Authors:  Levent M Akyürek; Manfred Boehm; Michelle Olive; Alex-Xianghua Zhou; Hong San; Elizabeth G Nabel
Journal:  Biochem Biophys Res Commun       Date:  2010-04-24       Impact factor: 3.575

6.  Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice.

Authors:  Yanqing Gong; Erika Hart; Aleksey Shchurin; Jane Hoover-Plow
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 7.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

8.  A Dual Role of Heme Oxygenase-1 in Angiotensin II-Induced Abdominal Aortic Aneurysm in the Normolipidemic Mice.

Authors:  Aleksandra Kopacz; Damian Klóska; Ewa Werner; Karolina Hajduk; Anna Grochot-Przęczek; Alicja Józkowicz; Aleksandra Piechota-Polańczyk
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600

9.  SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via activation of iNOS.

Authors:  Chek K Tan; Eddie H Tan; Baiwen Luo; Charlotte L Huang; Joachim S Loo; Cleo Choong; Nguan S Tan
Journal:  J Am Heart Assoc       Date:  2013-06-19       Impact factor: 5.501

10.  The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis.

Authors:  Kyle G Ingram; Carol D Curtis; Robert Silasi-Mansat; Florea Lupu; Courtney T Griffin
Journal:  PLoS Genet       Date:  2013-12-12       Impact factor: 5.917
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.